{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:33:32Z","timestamp":1791232412758,"version":"4.1.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2010,5,28]],"date-time":"2010-05-28T00:00:00Z","timestamp":1275004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Pazopanib is a recently approved, novel tyrosine kinase inhibitor specifically designed to impair angiogenesis by abrogating vascular endothelial growth factor receptor 2 (VEGFR-2) to exert its function. Pazopanib inhibits VEGF-induced endothelial cell proliferation in vitro and angiogenesis in vivo and demonstrates antitumor activity in mouse models. Furthermore, the pazopanib concentration resulting in maximal inhibition of VEGFR-2 phosphorylation in vivo was in line with the steady-state concentration required to inhibit growth of tumor xenografts, suggesting that pazopanib's mechanism of action is indeed through VEGFR-2 inhibition.<\/jats:p>\n               <jats:p>In a phase I trial, a generally well-tolerated dose was identified at which the majority of patients achieved pazopanib plasma concentrations above the concentration required for maximal in vivo inhibition of VEGFR-2 phosphorylation in preclinical models. Administered as monotherapy, evidence of antitumor activity was observed in phase II studies in several tumor types, including soft tissue sarcoma, renal cell cancer (RCC), ovarian cancer, and non-small cell lung cancer. Recently, the U.S. Food and Drug Administration granted approval for treatment with pazopanib in patients with RCC based on the longer progression-free survival time observed with this agent in a placebo-controlled, randomized trial. This review summarizes the preclinical and clinical pharmacokinetics and pharmacodynamics of pazopanib, as well as data on clinical activity, that ultimately resulted in its recent approval.<\/jats:p>","DOI":"10.1634\/theoncologist.2009-0274","type":"journal-article","created":{"date-parts":[[2010,5,29]],"date-time":"2010-05-29T00:58:33Z","timestamp":1275094713000},"page":"539-547","source":"Crossref","is-referenced-by-count":140,"title":["(Pre-)Clinical Pharmacology and Activity of Pazopanib, a Novel Multikinase Angiogenesis Inhibitor"],"prefix":"10.1093","volume":"15","author":[{"given":"Paul","family":"Hamberg","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap","family":"Verweij","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Sleijfer","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2010,5,28]]},"reference":[{"key":"2021122207520386500_R1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrc1093","article-title":"Tumorigenesis and the angiogenic switch","volume":"3","author":"Bergers","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"2021122207520386500_R2","first-page":"5407","article-title":"High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer","volume":"61","author":"Foekens","year":"2001","journal-title":"Cancer Res"},{"key":"2021122207520386500_R3","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S1470-2045(01)00556-3","article-title":"Vascular endothelial growth factor: Its prognostic, predictive, and therapeutic implications","volume":"2","author":"Toi","year":"2001","journal-title":"Lancet Oncol"},{"key":"2021122207520386500_R4","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","article-title":"Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer","volume":"21","author":"Kabbinavar","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122207520386500_R5","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"2021122207520386500_R6","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"2021122207520386500_R7","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"key":"2021122207520386500_R8","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1158\/1535-7163.MCT-07-0193","article-title":"Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity","volume":"6","author":"Kumar","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"2021122207520386500_R9","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2021122207520386500_R10","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43\u20139006 exhibits broad spectrum oral antitumor activity and targets RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"2021122207520386500_R11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11912-007-0007-2","article-title":"Pazopanib: A novel multitargeted tyrosine kinase inhibitor","volume":"9","author":"Sonpavde","year":"2007","journal-title":"Curr Oncol Rep"},{"key":"2021122207520386500_R12","doi-asserted-by":"crossref","first-page":"19478","DOI":"10.1073\/pnas.0609329103","article-title":"The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma","volume":"103","author":"Podar","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122207520386500_R13","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1158\/1078-0432.CCR-08-2740","article-title":"Phase I trial of pazopanib in patients with advanced cancer","volume":"15","author":"Hurwitz","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"suppl 2","key":"2021122207520386500_R14","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S1359-6349(09)70418-5","article-title":"Phase I study of pazopanib in hepatocellular carcinoma: Evaluation of clinical activity, pharmacokinetics and dynamic contrast enhanced MRI (DCE MRI)","volume":"7","author":"Yau","year":"2009","journal-title":"Eur J Cancer"},{"key":"2021122207520386500_R15","first-page":"142","article-title":"A phase I open-label study of the safety and pharmacokinetics of pazopanib and lapatinib administered concurrently [abstract 3088]","volume":"24","author":"De Jonge","year":"2006","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122207520386500_R16","first-page":"166","article-title":"Phase I study of the safety, tolerability, and pharmacokinetics (PK) of weekly paclitaxel administered in combination with pazopanib (GW786034) [abstract 3552]","volume":"26","author":"Tan","year":"2008","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122207520386500_R17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","article-title":"Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer","volume":"24","author":"Faivre","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122207520386500_R18","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1200\/JCO.2005.06.124","article-title":"Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43\u20139006 in patients with advanced refractory solid tumors","volume":"23","author":"Strumberg","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122207520386500_R19","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122207520386500_R20","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1200\/JCO.2008.21.6994","article-title":"Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma","volume":"28","author":"Hutson","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122207520386500_R21","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2008.21.3223","article-title":"Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: A phase II study from the European Organisation for Research and Treatment of Cancer\u2013Soft Tissue and Bone Sarcoma Group (EORTC study 62043)","volume":"27","author":"Sleijfer","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122207520386500_R22","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0959-8049(01)00398-7","article-title":"Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas","volume":"38","author":"Van Glabbeke","year":"2002","journal-title":"Eur J Cancer"},{"issue":"suppl 8","key":"2021122207520386500_R23","first-page":"viii211","article-title":"Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: Final results of a phase II study","volume":"19","author":"Friedlander","year":"2008","journal-title":"Ann Oncol"},{"issue":"suppl 8","key":"2021122207520386500_R24","first-page":"viii89","article-title":"Phase II study of pazopanib (GW786034) given preoperatively in stage I-II non-small cell lung cancer (NSCLC): A proof-of-concept study","volume":"19","author":"Altorki","year":"2008","journal-title":"Ann Oncol"},{"key":"2021122207520386500_R25","first-page":"45","article-title":"Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2 positive advanced or metastatic breast cancer [abstract 1016]","volume":"26","author":"Slamon","year":"2008","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122207520386500_R26","doi-asserted-by":"crossref","first-page":"4819","DOI":"10.1182\/blood-2009-02-207209","article-title":"Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: A phase 2 study of pazopanib (GW786034)","volume":"113","author":"Prince","year":"2009","journal-title":"Blood"},{"key":"2021122207520386500_R27","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/archderm.142.11.1477","article-title":"Hair depigmentation during chemotherapy with a class III\/V receptor tyrosine kinase inhibitor","volume":"142","author":"Routhouska","year":"2006","journal-title":"Arch Dermatol"},{"issue":"suppl 2","key":"2021122207520386500_R28","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1359-6349(09)70407-0","article-title":"Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism","volume":"7","author":"Xu","year":"2009","journal-title":"Eur J Cancer"},{"key":"2021122207520386500_R29","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","article-title":"Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma","volume":"17","author":"Motzer","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021122207520386500_R30","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1200\/JCO.2008.19.3342","article-title":"Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma","volume":"27","author":"Escudier","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122207520386500_R31","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122207520386500_R32","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"2021122207520386500_R33","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1200\/JCO.2008.16.9847","article-title":"Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206","volume":"26","author":"Rini","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122207520386500_R34","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/sj.bjc.6605167","article-title":"Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: A systematic review and indirect comparison of clinical effectiveness","volume":"101","author":"Thompson Coon","year":"2009","journal-title":"Br J Cancer"},{"key":"2021122207520386500_R35","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1001\/jama.295.21.2516","article-title":"Sunitinib in patients with metastatic renal cell carcinoma","volume":"295","author":"Motzer","year":"2006","journal-title":"JAMA"},{"key":"2021122207520386500_R36","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2005.02.2574","article-title":"Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma","volume":"24","author":"Motzer","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122207520386500_R37","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2009-0274","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2009-0274","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/15\/6\/539\/41843916\/oncolo_15_6_539.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/15\/6\/539\/41843916\/oncolo_15_6_539.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T11:22:16Z","timestamp":1640172136000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/15\/6\/539\/6399187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,28]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2010,5,28]]},"published-print":{"date-parts":[[2010,6,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2009-0274","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2010,6,1]]},"published":{"date-parts":[[2010,5,28]]}}}